Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International Inc (NASDAQ: DYAI) delivers innovative biotechnological solutions through its proprietary C1 and Dapibus™ platforms, serving pharmaceutical developers and industrial partners worldwide. This news hub provides investors and industry professionals with timely updates on strategic developments, financial milestones, and scientific advancements.
Access consolidated information on DYAI's licensing agreements, product pipeline progress, and operational updates. Our repository includes press releases covering clinical collaborations, manufacturing expansions, and technology applications across vaccine development, therapeutic proteins, and sustainable food production sectors.
Key updates include earnings announcements, partnership disclosures with leading biopharma entities, regulatory filings, and platform efficiency improvements. Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis.
Dyadic International, Inc. (NASDAQ: DYAI) will report its financial results for the first quarter of 2023 on May 10, 2023, at 5:00 p.m. ET. This follows the company's focus on innovative microbial platforms aimed at increasing global protein bioproduction and improving access to biopharmaceutical products for human and animal health. Dyadic utilizes advanced technology based on the fungus Thermothelomyces heterothallica, enhancing the development and manufacturing of biologics. Their lead asset, DYAI-100, is a COVID-19 vaccine candidate, showcasing the company's commitment to addressing unmet clinical needs. A webcast of the conference call will be available post-event for investors and stakeholders.
Dyadic International, Inc. (NASDAQ: DYAI) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA." This patent is expected to provide protection through 2038 and covers the development and manufacture of seasonal and pandemic influenza vaccines using Dyadic’s C1 protein production platform. The human influenza vaccine market is valued at approximately $8 billion, projected to exceed $12 billion by 2028. CEO Mark Emalfarb highlighted the urgent need for efficient vaccine manufacturing platforms, especially in light of recent health crises. The patent strengthens Dyadic's intellectual property, bolstering its capacity to produce antigens and therapeutic proteins across diverse applications including oncology and diabetes.
FAQ
What is the current stock price of Dyadic Intl Del (DYAI)?
What is the market cap of Dyadic Intl Del (DYAI)?
